There Is No Public Safety Crisis: The Truth About Botox Regulation

The narrative around botulinum toxin (commonly referred to as “Botox”) being a public safety concern is not supported by evidence.

This treatment has been used for decades and has a strong safety profile when administered by trained professionals. Yet recent campaigns and lobbying efforts have exaggerated rare occurrences to push for disproportionate regulation, often excluding a significant portion of the workforce.

Let’s look at the reality:

MHRA Data Speaks for Itself

Over the past 25 years, only 188 adverse events involving botulinum toxin have been reported to the Medicines and Healthcare Products Regulatory Agency (MHRA).

Compare that to the estimated upwards of 1 million botulinum treatments administered annually in the UK. The incident rate is statistically negligible.

Most importantly:

No deaths have been recorded from these adverse events.
No hospitalisations.
Complete recovery in all cases.

These are the outcomes over a period of two and a half decades of use. This does not constitute a crisis.

Insurers Continue to Support the Sector

If there were a genuine, widespread safety concern, insurance providers would be the first to respond.

Instead, they continue to cover qualified, trained non-medical practitioners. Premiums remain stable. Coverage is active. There has been no withdrawal of support.

Insurers assess real-world data, not speculation, media headlines, or pressure from lobbying groups.

The Real Issue: Regulatory Capture and Exclusion

The attempt to label Botox as a public safety issue is a strategic move to restrict access and control who can practice in this sector. This disproportionately affects the non-medical, vocational workforce, which is predominantly composed of women and small business owners.

We have seen this pattern before:

During the COVID-19 pandemic, the aesthetics sector, particularly beauty and non-medical services, was the last to reopen, while others reopened earlier with fewer restrictions.
Now, under the guise of “safety,” the same groups are attempting to exclude skilled professionals and centralise power, often under organisations that were not democratically elected or representative.

Licensing Proposals Lack Democratic Foundation

The Joint Council for Cosmetic Practitioners (JCCP) has repeatedly positioned itself as an authority, yet it does not represent the full breadth of the aesthetics industry. Its proposals have historically excluded:

Vocationally trained professionals
Small business voices
Client choice and consumer perspective

We are calling for a complete reset of the current licensing and regulatory proposals. This call has been echoed by MPs, legal experts, and members of the Women and Equalities Committee, who have acknowledged the need to return to first principles and include all legitimate stakeholders in the process.

Clarifying the VAT and Medical Argument

Some organisations argue that aesthetic injectables are “healthcare” when seeking exemptions from tax, while simultaneously describing them as “cosmetic” when it suits another agenda.

The MHRA, HMRC, and Government guidance make it clear:

Elective aesthetic injectables are not medical treatments.
They are cosmetic procedures and taxed accordingly.

Attempting to employ conflicting narratives, depending on the audience, undermines public trust and misleads policymakers.

A Thriving Sector Under Threat

The non-medical aesthetics sector:

Contributes millions in tax revenue
Supports tens of thousands of jobs
Provides accessible treatments to a wide range of clients

The non-medical aesthetic sector is a legitimate, regulated, and thriving part of the UK economy.

To characterise it as dangerous or rogue is not only inaccurate, it is damaging. It risks pushing businesses to collapse, increasing unemployment, and narrowing access for clients.

What We Stand For

At the Independent Aesthetics Practitioners Register (IAP), we advocate for:

Evidence-based policy
Fair, inclusive regulation
Recognition of vocational qualifications and professional competency

This conversation must move away from fear-based lobbying and back to data, integrity, and proper consultation.

We urge regulators, MPs, and the public to examine the facts, not the headlines, and ensure that any future licensing framework is built on truth, transparency, and inclusion, not special interest influence.